AdvaMed

Incredible to consider the implications here of better patient access to high quality care and resulting good outcomes.

At AdvaMed, we're dedicated to advancing innovation, empowering and convening the #medtech industry, and enhancing patient outcomes. This mission is at the heart of The MedTech Conference, taking place October 5-8, 2025, in San Diego. This year’s #MTC25 conference comes at a critical time for the medtech industry—providing direct access to cutting-edge education, company presentations, and the latest in innovation. Join us for an unparalleled opportunity to drive innovation and shape the future of health care. We’ve remained committed to supporting you and the industry through challenging times—focusing on innovation and better patient outcomes. That’s why we’re giving you more time to take advantage of this member offer. Sign up for MTC25 Flex Pass with no commitment and save up to 40% on your all-access registration later. Lock in and save by April 22: https://lnkd.in/gDFWFM39

Fascinating, valuable health tech advancements.

The Imaging Wire published an insightful story about the new Health Tech Investment Act in the U .S. Senate. Highlights: ➡️Reimbursement is one of the major stumbling blocks holding back wider clinical adoption of artificial intelligence. But new legislation was introduced in the U.S. Congress last week that could ease AI’s reimbursement path. ➡️Reimbursement drives clinical AI adoption but CMS uses a patchwork system governing reimbursement, from temporary codes like New Technology Add-On Payment codes that expire after 2-3 years to G-codes for procedures that don’t have CPT codes, on up to the holy grail of medical reimbursement: Category I codes. ➡️The new legislation would simplify the situation by setting up a dedicated Medicare coverage pathway for AI-enabled medical devices approved by the FDA (called “algorithm-based healthcare services”). AdvaMed looks forward to the advancement of the Health Tech Investment Act to provide more patients with transformative AI-enabled health tech. https://lnkd.in/e8D_2GiS

Last week, the Senate finished confirming the federal agency and subagency leaders that oversee every aspect of medtech’s pivotal role as the backbone of our health care system. We now have in place Secretary of HHS Kennedy, FDA Commissioner Makary, CMS Administrator Oz, and NIH Director Bhattacharya. Over the next four years, we have the opportunity to improve and strengthen our public/private partnership in order to usher in a new golden age of health care and medical technology innovation.  Secretary Kennedy has established the Administration’s overall vision with his “Make America Healthy Again” initiative. I have spoken with Secretary Kennedy, and I know he takes his role and responsibility seriously. I made it clear that our industry shares his vision for a healthier America, and I look forward to working with him and his team in the years ahead. His motto could easily have been the medtech industry’s motto over the past century or more: Our entire mission is to ensure patients live healthier and longer lives. We stand ready to work with him to ensure that doctors and their patients have access to the leading-edge medtech they need, when they need it. FDA Commissioner Marty Makary M.D., M.P.H., CMS Administrator Mehmet Oz, and NIH Director Jay Bhattacharya all have the advantage of hands-on, real-world experience with our technologies throughout their renowned careers as practitioners. They know what it means to have the most advanced medical technologies available every day as they worked to heal patients. On behalf of the entire industry, we welcome these leaders and their teams, and we look forward to working with them on our shared vision of a healthier America.  

Wonderful spotlight on a game-changing application of AI in medtech.

AdvaMed thanks Senators Mike Rounds and Martin Heinrich for introducing the Health Tech Investment Act, which will establish a stable payment pathway for artificial intelligence (AI) enabled medical technologies. Scott Whitaker, President and CEO of AdvaMed, said: “With AI-enabled medical technologies already making remarkable strides in patient care, and with even more incredible strides ahead of us, now is the time to establish a predictable reimbursement pathway. We thank Senators Rounds and Heinrich for their leadership and strongly urge Congress to pass this bipartisan legislation. It is critical to advancing the medical progress upon which patients depend and which is being driven by medtech.” We look forward to working with lawmakers and the Trump administration to usher in the golden age of innovative #AI and benefit patient care. Read more: https://lnkd.in/ecJ4gByc

We are encouraged by the President’s announcement of a 90-day pause on reciprocal tariffs. This is an important decision that restores some short-term certainty to global markets, including the American medtech industry, which is number one globally.     Moving forward, we will spend the next 90 days working with the President and his senior team to ensure the unique role of the medtech industry is protected, with the hope that the ultimate outcome is “zero for zero” tariffs on medtech with all key trading partners. 

AI is transforming novel technologies like adaptive deep brain stimulation, personalizing the therapy based on a patient’s brain activity in real time. Approved by the FDA earlier this year, the first such system is helping patients with Parkinson’s regain function in their daily lives. Keith Krehbiel, who was diagnosed with Parkinson’s in his 40s, now age 70, said of the therapy, “The tremor’s gone, dyskinesia is gone, and I don’t have that brain fog that I used to have when I was taking so many meds.” This breakthrough shows what’s possible when research, #medtech innovation, and the FDA come together: more precise, personalized, and targeted health care treatments. That’s why AdvaMed continues to advocate for policies supporting our member companies that are at the forefront of accelerating access to transformative technologies like adaptive deep brain stimulation. All patients deserve not only treatments that extend their lives, but also a chance to feel like themselves again. Click the link to learn more about this life-changing treatment. https://lnkd.in/g5JDdE5r

We congratulate Dr. Mehmet Oz on his confirmation last night as Administrator of CMS. As a heart surgeon who helped develop medtech to treat heart conditions, he understands that medical technology is the backbone of our health care system and is critical to improving and saving lives. His call for faster Medicare coverage of FDA-cleared breakthrough technologies is evidence of that. We look forward to working with him to advance this longstanding priority of ours.  CMS oversees health care for 160 million Americans, making its decisions key to ensuring greater access to the transformative medtech making headlines every day. Medicare coverage and reimbursement decisions extend beyond Medicare, influencing private health insurance coverage as well. We look forward to working with him on the processes that work well and those in need of modernization to serve patients better. His commitment to ensuring that CMS provides Americans "access to superb care" is welcome.  We look forward to Dr. Oz’s leadership and stand ready to help him achieve our shared goal of helping patients achieve their best health.